Traws Pharma, Inc. Proceeds from Warrant Exercises
Traws Pharma, Inc. (TRAW) reported Proceeds from Warrant Exercises of $26.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromWarrantExercises · last filed 2026-08-14
- Traws Pharma, Inc. proceeds from warrant exercises for the quarter ending 2025-12-31 was $10.00K.
- Traws Pharma, Inc. proceeds from warrant exercises for the quarter ending 2025-09-30 was $0.00.
- Traws Pharma, Inc. proceeds from warrant exercises for the quarter ending 2025-06-30 was $2.00K.
- Traws Pharma, Inc. proceeds from warrant exercises for the quarter ending 2025-03-31 was $14.00K.
- Traws Pharma, Inc. proceeds from warrant exercises for fiscal 2025 was $26.00K.
- Traws Pharma, Inc. proceeds from warrant exercises for fiscal 2021 was $495.00K, a 95.19% decline from fiscal 2020.
- Traws Pharma, Inc. proceeds from warrant exercises for fiscal 2020 was $10.29M, a 112.07% increase from fiscal 2019.
- Traws Pharma, Inc. proceeds from warrant exercises for fiscal 2019 was $4.85M.
| Period end | Proceeds from Warrant Exercises 1 month | Proceeds from Warrant Exercises 3 month | Proceeds from Warrant Exercises 6 month | Proceeds from Warrant Exercises 9 month | Proceeds from Warrant Exercises 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $10.00K derived: sum of 2 quarters · filed 2026-04-15 | $12.00K derived: sum of 3 quarters · filed 2026-08-14 | $26.00K 10-K · filed 2026-04-15 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.00K derived: sum of 2 quarters · filed 2026-08-14 | $16.00K 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $16.00K 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | $14.00K 10-Q · filed 2026-05-15 | ||||
| 2021-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $15.00K derived: sum of 2 quarters · filed 2023-03-30 | $15.00K derived: sum of 3 quarters · filed 2023-03-30 | $495.00K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $480.00K 10-Q · filed 2022-11-14 | $758.00K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $480.00K 10-Q · filed 2022-08-15 | $758.00K derived: sum of 3 quarters · filed 2022-08-15 | $3.48M derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $480.00K 10-Q · filed 2022-05-13 | $758.00K derived: sum of 2 quarters · filed 2022-05-13 | $3.48M derived: sum of 3 quarters · filed 2022-05-13 | $5.06M derived: sum of 4 quarters · filed 2022-05-13 | |
| 2020-12-31 | $278.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $3.00M derived: sum of 2 quarters · filed 2022-03-21 | $4.58M derived: sum of 3 quarters · filed 2022-03-21 | $10.29M 10-K · filed 2022-03-21 | |
| 2020-09-30 | $2.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $4.30M derived: sum of 2 quarters · filed 2021-11-15 | $10.02M 10-Q · filed 2021-11-15 | $14.84M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-08-12 | $10.00M 10-Q · filed 2020-11-16 | ||||
| 2020-06-30 | $1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $7.30M 10-Q · filed 2021-08-16 | $12.12M derived: sum of 3 quarters · filed 2021-08-16 | $12.12M derived: sum of 4 quarters · filed 2021-08-16 | |
| 2020-03-31 | $5.72M 10-Q · filed 2021-05-17 | $10.54M derived: sum of 2 quarters · filed 2021-05-17 | $10.54M derived: sum of 3 quarters · filed 2021-05-17 | $10.54M derived: sum of 4 quarters · filed 2021-05-17 | |
| 2019-12-31 | $5.70M 10-K · filed 2020-03-27 | $4.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $4.82M derived: sum of 2 quarters · filed 2021-03-18 | $4.82M derived: sum of 3 quarters · filed 2021-03-18 | $4.85M 10-K · filed 2021-03-18 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $0.00 derived: sum of 2 quarters · filed 2020-11-16 | $33.00K 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $33.00K 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | $33.00K 10-Q · filed 2020-05-15 | ||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $573.00K derived: sum of 2 quarters · filed 2019-11-12 | $589.00K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $573.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $589.00K 10-Q · filed 2019-08-14 | |||
| 2018-03-31 | $16.00K 10-Q · filed 2019-05-15 | ||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $0.00 derived: sum of 2 quarters · filed 2015-03-30 | $2.17M 10-K · filed 2015-03-30 | ||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $2.17M 10-Q · filed 2013-11-14 | |||
| 2012-06-30 | $2.17M 10-Q · filed 2013-09-06 | ||||
| 2011-12-31 | $1.92M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |